Leo Pharma AS
Latest From Leo Pharma AS
Scrip takes a look at Korean out-licensing deal trends and rankings in 2018, finding biotech-related transactions were dominant.
Bayer's Consumer Health chief Heiko Schipper hopes a focus on innovation and a leaner portfolio will help return business to mid-single-digit growth by 2022. German firm has identified North American business as the "key area to fix."
Glenmark Pharmaceuticals has tiptoed into the US branded dermatology segment by buying out a range of products from Exeltis. It hopes to build on this base with additional assets, alongside its generics business.
Following last December’s partnership in CNS with Autifony, BI undertakes a screening collaboration with Domain. Leo maintains its busy deal-making pace, partnering in dermatology with Evotec.
- Specialty Pharmaceuticals
- Therapeutic Areas
- Blood & Coagulation Disorders & Products
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Renal System
- Respiratory, Pulmonary
- Leo Pharmaceutical Products Ltd.
- Western Europe
- Parent & Subsidiaries
- Leo Pharma AS
- Senior Management
Gitte P Aabo, Pres. & CEO
Anders Kronborg, EVP, Global Fin. & Bus. Services
Kim Kjoller, EVP, Global R&D
- Contact Info
Leo Pharma AS
Phone: (45) 4494 5888
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.